Loading…

Efficacy of the adjuvanted recombinant zoster vaccine (RZV) by sex, geographic region, and geographic ancestry/ethnicity: A post-hoc analysis of the ZOE-50 and ZOE-70 randomized trials

Highlights•RZV efficacy against HZ or PHN was similar in women and men. •In ≥50-year-olds, efficacy against HZ was 95.7–97.2% across geographic regions. •In ≥70-year-olds, efficacy against HZ and PHN was 86.8–100% across geographic regions. •No major efficacy differences observed against HZ and PHN...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2019-10, Vol.37 (43), p.6262-6267
Main Authors: Willer, David O, Oostvogels, Lidia, Cunningham, Anthony L, Gervais, Pierre, Gorfinkel, Iris, Hyung Kim, Joon, Talarico, Carla, Wascotte, Valentine, Zahaf, Toufik, Colindres, Romulo, Schuind, Anne
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights•RZV efficacy against HZ or PHN was similar in women and men. •In ≥50-year-olds, efficacy against HZ was 95.7–97.2% across geographic regions. •In ≥70-year-olds, efficacy against HZ and PHN was 86.8–100% across geographic regions. •No major efficacy differences observed against HZ and PHN by geographic ancestry/ethnicity. •RZV efficacy against HZ and PHN in these subsets was consistent with the overall ZOE-50/70 population.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2019.09.028